Pfizer Strengthens Infant Food Manufacturing Capabilities in Asia With $100m Investment
Pfizer has invested $100m in the expansion of its Singapore Nutrition Plant, which manufactures nutritional products for infants and children. The expansion, which brings the total investment in the plant to $372m, makes it one of the largest nutritional plants worldwide.
The expansion of the plant to 91,963 sq m (the equivalent of 17 football fields) has boosted the plant’s production capacity by 50% and increased its ability to supply nutrition products to Singapore and key markets such as China, Indonesia, Malaysia, Pakistan, Sri Lanka, Thailand, Taiwan, Hong Kong and Vietnam.
As part of the Singapore plant expansion, Pfizer has added over 100 new positions in the past year, bringing its staff strength to 587 people in total.
The plant is part of Pfizer Global Manufacturing’s Nutrition Operating Unit, which is dedicated to manufacturing nutrition products used by infants and children. The network also operates manufacturing facilities in Ireland, China, Mexico and the Philippines.
Formerly a Wyeth operation, the Singapore plant was integrated into Pfizer Singapore following Pfizer’s acquisition of Wyeth in October 2009. The expansion was completed in June 2010.
